438 related articles for article (PubMed ID: 28207639)
1. Predictors of Waitlist Mortality in Portopulmonary Hypertension.
DuBrock HM; Goldberg DS; Sussman NL; Bartolome SD; Kadry Z; Salgia RJ; Mulligan DC; Kremers WK; Kawut SM; Krowka MJ; Channick RN
Transplantation; 2017 Jul; 101(7):1609-1615. PubMed ID: 28207639
[TBL] [Abstract][Full Text] [Related]
2. Mending the Model for End-Stage Liver Disease: An in-depth review of the past, present, and future portopulmonary hypertension Model for End-Stage Liver Disease exception.
DuBrock HM; Del Valle KT; Krowka MJ
Liver Transpl; 2022 Jul; 28(7):1224-1230. PubMed ID: 35106916
[TBL] [Abstract][Full Text] [Related]
3. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
[TBL] [Abstract][Full Text] [Related]
4. MELD exceptions for portopulmonary hypertension: current policy and future implementation.
Goldberg DS; Batra S; Sahay S; Kawut SM; Fallon MB
Am J Transplant; 2014 Sep; 14(9):2081-7. PubMed ID: 24984921
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of portopulmonary hypertension patients after liver transplantation.
Khaderi S; Khan R; Safdar Z; Stribling R; Vierling JM; Goss JA; Sussman NL
Liver Transpl; 2014 Jun; 20(6):724-7. PubMed ID: 24648168
[TBL] [Abstract][Full Text] [Related]
6. Sex Differences in Portopulmonary Hypertension.
DuBrock HM; Cartin-Ceba R; Channick RN; Kawut SM; Krowka MJ
Chest; 2021 Jan; 159(1):328-336. PubMed ID: 32798521
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes in liver transplant recipients with Model for End-stage Liver Disease scores of 40 or higher: a decade-long experience.
Panchal HJ; Durinka JB; Patterson J; Karipineni F; Ashburn S; Siskind E; Ortiz J
HPB (Oxford); 2015 Dec; 17(12):1074-84. PubMed ID: 26373873
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes After Liver Transplantation in Patients With Portopulmonary Hypertension.
Cartin-Ceba R; Burger C; Swanson K; Vargas H; Aqel B; Keaveny AP; Heimbach J; Taner T; Nyberg S; Rosen C; Cajigas H; DuBrock H; Krowka MJ
Transplantation; 2021 Oct; 105(10):2283-2290. PubMed ID: 33065725
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation.
Sundaram V; Jalan R; Wu T; Volk ML; Asrani SK; Klein AS; Wong RJ
Gastroenterology; 2019 Apr; 156(5):1381-1391.e3. PubMed ID: 30576643
[TBL] [Abstract][Full Text] [Related]
10. Portopulmonary hypertension: survival and prognostic factors.
Le Pavec J; Souza R; Herve P; Lebrec D; Savale L; Tcherakian C; Jaïs X; Yaïci A; Humbert M; Simonneau G; Sitbon O
Am J Respir Crit Care Med; 2008 Sep; 178(6):637-43. PubMed ID: 18617641
[TBL] [Abstract][Full Text] [Related]
11. Portopulmonary hypertension: Results from a 10-year screening algorithm.
Krowka MJ; Swanson KL; Frantz RP; McGoon MD; Wiesner RH
Hepatology; 2006 Dec; 44(6):1502-10. PubMed ID: 17133488
[TBL] [Abstract][Full Text] [Related]
12. Portopulmonary hypertension: Still an appropriate consideration for liver transplantation?
Verma S; Hand F; Armstrong MJ; de Vos M; Thorburn D; Pan T; Klinck J; Westbrook RH; Auzinger G; Bathgate A; Masson S; Holt A; Houlihan DD; Ferguson JW
Liver Transpl; 2016 Dec; 22(12):1637-1642. PubMed ID: 27593213
[TBL] [Abstract][Full Text] [Related]
13. Center variation in the use of nonstandardized model for end-stage liver disease exception points.
Goldberg DS; Makar G; Bittermann T; French B
Liver Transpl; 2013 Dec; 19(12):1330-42. PubMed ID: 24039090
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension.
Jose A; Shah SA; Anwar N; Jones CR; Sherman KE; Elwing JM
Liver Transpl; 2021 Dec; 27(12):1811-1823. PubMed ID: 33964116
[TBL] [Abstract][Full Text] [Related]
15. Portopulmonary hypertension: an update.
Safdar Z; Bartolome S; Sussman N
Liver Transpl; 2012 Aug; 18(8):881-91. PubMed ID: 22674534
[TBL] [Abstract][Full Text] [Related]
16. Impact of MELD score implementation on liver allocation: experience at a Brazilian center.
da Silva Machado AG; de Medeiros Fleck A; Marroni C; Zanotelli ML; Cantisani G; de Mello Brandão AB
Ann Hepatol; 2013; 12(3):440-7. PubMed ID: 23619261
[TBL] [Abstract][Full Text] [Related]
17. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Goldberg D; French B; Abt P; Feng S; Cameron AM
Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
[TBL] [Abstract][Full Text] [Related]
18. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database.
Goldberg DS; Krok K; Batra S; Trotter JF; Kawut SM; Fallon MB
Gastroenterology; 2014 May; 146(5):1256-65.e1. PubMed ID: 24412528
[TBL] [Abstract][Full Text] [Related]
19. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.
Nobel YR; Goldberg DS
Transplantation; 2015 Nov; 99(11):2341-6. PubMed ID: 25989503
[TBL] [Abstract][Full Text] [Related]
20. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
